CG923308
/ Gyre Therapeutics
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
August 07, 2026
Gyre expects to submit Investigational New Drug (IND) applications in the United States and/or China in the first quarter of 2027 for…CG923308, a CDK2-Cyclin E dual degrader for solid tumor indications…
(GlobeNewswire)
IND • New trial • Solid Tumor
1 to 1
Of
1
Go to page
1